2007
Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenase‐deficient mice: evidence for glial dysfunction and reduced glutamate/glutamine cycling
Chowdhury GM, Gupta M, Gibson KM, Patel AB, Behar KL. Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenase‐deficient mice: evidence for glial dysfunction and reduced glutamate/glutamine cycling. Journal Of Neurochemistry 2007, 103: 2077-2091. PMID: 17854388, DOI: 10.1111/j.1471-4159.2007.04887.x.Peer-Reviewed Original ResearchMeSH KeywordsAcetatesAmino AcidsAnimalsAnimals, NewbornBlood GlucoseCarbon IsotopesCerebral CortexGamma-Aminobutyric AcidGlutamate-Ammonia LigaseGlutamic AcidGlutamineImage Processing, Computer-AssistedMagnetic Resonance SpectroscopyMiceMice, KnockoutNeurogliaSodium OxybateSuccinate-Semialdehyde DehydrogenaseTime FactorsConceptsSSADH deficiencyLevels of GABAGlutamate/glutamine cyclingSuccinic semialdehyde dehydrogenase‐deficient miceGlutamine-C4Cerebral metabolismCerebral glucoseCortical extractsGlial dysfunctionIntraperitoneal infusionSuccinic semialdehyde dehydrogenaseGABA-C2Excessive elevationNeurotransmitter glutamateGABA synthesisGABAMiceGHBGlutamateGlutamine metabolismAspartate C3GliaCortexGlutamine cyclingGlial substrate
1995
Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy
Mattson R, Petroff O, Rothman D, Behar K. Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurologica Scandinavica. Supplementum 1995, 92: 27-30. PMID: 7495186, DOI: 10.1111/j.1600-0404.1995.tb00496.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBrain GABA levelsGABA levelsBrain concentrationsNerve terminalsAdministration of vigabatrinClear dose-response relationshipLevels of GABAPartial epileptic seizuresAnti-epilepsy drugsPresynaptic nerve terminalsDose-response relationshipConcentration of GABASecondary generalizationClinical effectsClinical outcomesVigabatrin administrationClinical trialsPatient responseClinical studiesSynaptic transmissionBaseline valuesOptimal doseVigabatrin levelsVigabatrinEpileptic seizures